Research Article
Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
Table 5
Immune status of CRC patients before treatment began and after 6 cycles of adjuvant/palliative chemotherapy (FOLFOX4) without Uncaria tomentosa supply (C group) or receiving 300 mg/day of Uncaria tomentosa (UT group).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Data expressed as mean (SD); UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300 mg/daily (); C group: CRC patients received FOLFOX4 (). # between groups. |